Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil
Rev. Soc. Bras. Med. Trop
; Rev. Soc. Bras. Med. Trop;52: e20180272, 2019. tab, graf
Article
de En
| LILACS
| ID: biblio-1041550
Bibliothèque responsable:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.METHODS:
A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies.RESULTS:
IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year.CONCLUSIONS:
These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.Mots clés
Texte intégral:
1
Indice:
LILACS
Sujet Principal:
Amphotéricine B
/
Analyse coût-bénéfice
/
Leishmaniose viscérale
/
Méglumine
/
Antiprotozoaires
Type d'étude:
Diagnostic_studies
/
Health_economic_evaluation
/
Prognostic_studies
Limites du sujet:
Humans
Pays comme sujet:
America do sul
/
Brasil
langue:
En
Texte intégral:
Rev. Soc. Bras. Med. Trop
Thème du journal:
MEDICINA TROPICAL
Année:
2019
Type:
Article